Table 1.
Baseline patient characteristics.
| Characteristic | Patients (n) | (%) |
|---|---|---|
| Median age, y (range) | 58 (28~83) | |
| <65 | 143 | 69.4 |
| ≥65 | 63 | 30.6 |
| Gender | ||
| Male | 97 | 41.7 |
| Female | 109 | 58.3 |
| ECOG performance status | ||
| 0~1 | 153 | 74.3 |
| 2 | 53 | 25.7 |
| Histology | ||
| Adenocarcinoma | 174 | 84.5 |
| Squamous cell | 2 | 0.9 |
| Large cell | 7 | 3.4 |
| Adeno-squamous | 14 | 6.8 |
| NOS | 9 | 4.4 |
| Disease stage | ||
| IIIB | 39 | 18.9 |
| IV | 167 | 81.1 |
| Smoking status | ||
| Non-smoker | 125 | 60.7 |
| Present or former smoker | 81 | 39.3 |
| Metastases number | ||
| 1 | 79 | 38.3 |
| 2 | 25 | 12.1 |
| 3 | 31 | 15.1 |
| 4 | 42 | 20.4 |
| 5 | 29 | 14.1 |
| EGFR mutation | ||
| Exon 19 deletion | 89 | 43.2 |
| Exon 21 L858R | 117 | 56.8 |
| EGFR TKIs | ||
| Gefitinib | 107 | 51.9 |
| Erlotinib | 47 | 22.8 |
| Icotinib | 52 | 25.3 |
| Response to first-line EGFR TKIs | ||
| Partial or complete response | 140 | 68.0 |
| Stable disease | 41 | 19.9 |
| Disease progression | 25 | 12.1 |
| Oligoprogressive symptom | ||
| Symptomatic | 71 | 34.5 |
| Asymptomatic | 135 | 65.5 |
| Second- or further-line treatment | ||
| Chemotherapy | 164 | 79.6 |
| Osimertinib±chemotherapy | 11 | 5.4 |
| CTHM | 31 | 15.0 |
| Metastasis location | ||
| Brain | 124 | 60.2 |
| Bone | 86 | 41.7 |
| Adrenal | 35 | 17.0 |
| Lung | 40 | 19.4 |
| Liver | 18 | 8.7 |
| Chest wall | 10 | 4.9 |
| Neck lymph nodes | 9 | 4.4 |
| Intestine | 1 | 0.5 |
| LAT for oligometastasis | ||
| Brain | 124 | |
| Whole-brain irradiation | 23 | 18.5 |
| SRS | 89 | 71.8 |
| Surgery + whole-brain irradiation | 12 | 9.7 |
| Bone | 86 | |
| Surgery + EBRT (30 Gy) | 4 | 4.7 |
| EBRT (30-40 Gy) | 82 | 95.3 |
| Adrenal | 35 | |
| Surgery | 10 | 28.6 |
| SBRT | 16 | 45.7 |
| EBRT (45-50 Gy) | 9 | 25.7 |
| Lung | 40 | |
| SBRT | 26 | 65.0 |
| EBRT (55-63 Gy) Surgery |
11 3 |
27.5 7.5 |
| Liver | 18 | |
| Radiofrequency ablation | 16 | 88.9 |
| Surgery | 2 | 11.1 |
| Chest wall | 10 | |
| EBRT (45-55Gy) | 10 | 100.0 |
| Neck lymph nodes | 9 | |
| EBRT (55-63Gy) | 9 | 100.0 |
| Intestine | 1 | |
| Surgery | 1 | 100.0 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
LAT, local ablative therapy; SBRT, stereotactic body radiation therapy; SRS, stereotactic radiosurgery; EBRT, external beam radiotherapy; RFA, radio frequency ablation; CTHM, Chinese traditional herbal medicine.